Study in Microbiology Spectrum reveals BPD-9, a new compound from sanguinarine, effectively targets drug-resistant Mycobacterium tuberculosis.

A study in *Microbiology Spectrum* reveals BPD-9, a new semi-synthetic compound from sanguinarine, that effectively targets Mycobacterium tuberculosis, including drug-resistant strains. It shows promise against dormant and intracellular bacteria, which challenge current TB treatments. BPD-9 may also aid in fighting non-tuberculous mycobacterial infections, highlighting its potential for clinical use and further research in antibiotic resistance.

October 03, 2024
4 Articles